ArticleCancers2021

MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma.

Vera Miranda-Gonçalves et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.